Use of high dose cyproterone acetate and risk of intracranial meningioma in women: cohort study

Study (n=253,777; 139,222 exposed) reports a strong dose-effect relation between use of cyproterone acetate and risk of intracranial meningiomas (adjusted hazard ratio 6.6, 95% CI 4.0 to 11.1); and a noticeable reduction in risk was observed after discontinuation of treatment.

British Medical Journal